Very low-dose direct oral anticoagulants combined with platelet inhibitors in coronary artery disease: ready for widespread use? | Zendy

M. N�gele | Zendy; Hans-Jrg Beer | Zendy

Open Access

Very low-dose direct oral anticoagulants combined with platelet inhibitors in coronary artery disease: ready for widespread use?

Author(s) -

M. N�gele,

Hans-Jrg Beer

Publication year - 2019

Publication title -

cardiovascular medicine

Language(s) - English

Resource type - Journals

eISSN - 1664-204X

pISSN - 1664-2031

DOI - 10.4414/cvm.2019.02062

Subject(s) - medicine , rivaroxaban , ticagrelor , prasugrel , coronary artery disease , acute coronary syndrome , cardiology , concomitant , myocardial infarction , platelet aggregation inhibitor , stroke (engine) , clopidogrel , intensive care medicine , warfarin , aspirin , atrial fibrillation , mechanical engineering , engineering

Very low-dose anticoagulation in the form of rivaroxaban twice daily is a welcoming addition to the current antithrombotic arsenal in high-risk patients with acute coronary syndrome or stable coronary artery disease. Adequate patient selection in line with the entry criteria of the approval trials appears to be critical to avoid excessive bleeding.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research